Strategic Acquisition Potential cross-sell or integration opportunities with healthōme following its acquisition of Kailos Genetics, enabling expanded access to clinical-grade genetic testing within a broader health navigation platform.

Clinical Genomics Opportunity to partner with healthcare systems and labs on pharmacogenomics and genetic screening panels, leveraging Kailos’s CLIA-certified lab capabilities to onboard payors and employers needing genetic testing services.

Workplace Testing Continue and expand workplace health programs (Assure Sentinel) with employers seeking recurring infectious disease testing and biosurveillance, targeting mid-size organizations in industries with high contact or onsite presence.

Eye Gene Network Leverage Advancing Sight Network collaboration to offer genetic screening panels for ophthalmology research and post-mortem tissue programs, offering research partners and academic medical centers access to specialized panels.

Growth Readiness Target small-to-mid biotech and CRO/CMO partners by highlighting scalable sequencing capabilities, and potential for co-development of targeted panels, given Kailos’s funding scale and revenue footprint in the 1–10M range.